P0886: Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatmentexperienced trial.

Publication Type:

Journal Article

Source:

J Hepatol, Volume 62, p.Supplement 2:S674-5 (2015)
Top